Literature DB >> 22817716

The self-perpetuating tau truncation circle.

Norbert Zilka1, Branislav Kovacech, Peter Barath, Eva Kontsekova, Michal Novák.   

Abstract

Pathological truncations of human brain proteins represent the common feature of many neurodegenerative disorders including AD (Alzheimer's disease), Parkinson's disease and Huntington's disease. Protein truncations significantly change the structure and function of these proteins and thus can engender their pathological metamorphosis. We have shown previously that truncated forms of tau protein are contained in the core of the paired helical filaments that represent the main constituent of neurofibrillary pathology. Recently, we have identified truncated tau species of a different molecular signature. We have found that tau truncation is not produced by a random process, but rather by highly specific proteolytic cleavage and/or non-enzymatic fragmentation. In order to characterize the pathophysiology of AD-specific truncated tau species, we have used a transgenic rat model for AD expressing human truncated tau. Expression of the tau protein induces the formation of novel truncated tau species that originate from both transgenic human tau and endogenous rat tau proteins. Moreover, these truncated tau proteins are found exclusively in the misfolded fraction of tau, suggesting that they actively participate in the tau misfolding process. These findings corroborate further the idea that the appearance of truncated tau species starts a self-perpetuating cycle of further tau protein truncation leading to and accelerating tau misfolding and formation of neurofibrillary pathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22817716     DOI: 10.1042/BST20120015

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  20 in total

1.  A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.

Authors:  C Laurent; S Burnouf; B Ferry; V L Batalha; J E Coelho; Y Baqi; E Malik; E Mariciniak; S Parrot; A Van der Jeugd; E Faivre; V Flaten; C Ledent; R D'Hooge; N Sergeant; M Hamdane; S Humez; C E Müller; L V Lopes; L Buée; D Blum
Journal:  Mol Psychiatry       Date:  2014-12-02       Impact factor: 15.992

Review 2.  Physiological functions and clinical implications of the N-end rule pathway.

Authors:  Yujiao Liu; Chao Liu; Wen Dong; Wei Li
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

3.  Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease.

Authors:  Bhumsoo Kim; Carey Backus; Sangsu Oh; Eva L Feldman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  First-in-Rat Study of Human Alzheimer's Disease Tau Propagation.

Authors:  Tomas Smolek; Santosh Jadhav; Veronika Brezovakova; Veronika Cubinkova; Bernadeta Valachova; Petr Novak; Norbert Zilka
Journal:  Mol Neurobiol       Date:  2018-05-16       Impact factor: 5.590

5.  Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.

Authors:  Maxime Derisbourg; Coline Leghay; Giovanni Chiappetta; Francisco-Jose Fernandez-Gomez; Cyril Laurent; Dominique Demeyer; Sébastien Carrier; Valérie Buée-Scherrer; David Blum; Joëlle Vinh; Nicolas Sergeant; Yann Verdier; Luc Buée; Malika Hamdane
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

6.  First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.

Authors:  Eva Kontsekova; Norbert Zilka; Branislav Kovacech; Petr Novak; Michal Novak
Journal:  Alzheimers Res Ther       Date:  2014-08-01       Impact factor: 6.982

7.  Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.

Authors:  Eva Kontsekova; Norbert Zilka; Branislav Kovacech; Rostislav Skrabana; Michal Novak
Journal:  Alzheimers Res Ther       Date:  2014-08-01       Impact factor: 6.982

Review 8.  Nuclear Tau and Its Potential Role in Alzheimer's Disease.

Authors:  Mahmoud Bukar Maina; Youssra K Al-Hilaly; Louise C Serpell
Journal:  Biomolecules       Date:  2016-01-07

9.  What Renders TAU Toxic.

Authors:  Jürgen Götz; Di Xia; Gerhard Leinenga; Yee Lian Chew; Hannah Nicholas
Journal:  Front Neurol       Date:  2013-06-10       Impact factor: 4.003

10.  Subacute Changes in Cleavage Processing of Amyloid Precursor Protein and Tau following Penetrating Traumatic Brain Injury.

Authors:  Casandra M Cartagena; Andrea Mountney; Hye Hwang; Adam Swiercz; Zoe Rammelkamp; Angela M Boutte; Deborah A Shear; Frank C Tortella; Kara E Schmid
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.